Bloodstream infections demand answers fast – especially when timing can influence clinical decisions. Traditional workflows often require more time than critically ill patients can spare. As sepsis and antimicrobial resistance rates continue to rise, the need for earlier clarity has never been greater (1).
Built on the trusted foundation of respiratory, meningitis, and gastrointestinal syndromic panels, we are now preparing to introduce new bloodstream infection panels (BCID) designed to deliver rapid, actionable insights when they matter most.
References:
1. Tosas AO, et al. Global antibiotic resistance surveillance report 2025: WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). Geneva, Switzerland: World Health Organization; 2025.
The QIAstat-Dx BCID Plus AMR Panels are currently under development and are not commercially available. Availability may vary by country and is subject to applicable regulatory requirements.